Treatment of attention-deficit/hyperactivity disorder
Patent 6046193 Issued on April 4, 2000. Estimated Expiration Date: 
September 17, 2018. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
September 17, 2018. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesSubstituted morpholine derivatives and compositions Substituted morpholine derivatives and pharmaceutical compositions Potentiation of drug response Treatment of attention-deficit/hyperactivity disorder Treatment of attention-deficit/hyperactivity disorder Patent #: 5696168 InventorAssigneeApplicationNo. 156284 filed on 09/17/1998US Classes:514/239.2, The chalcogen is bonded directly to two carbon atoms514/238.8, Chalcogen attached indirectly to the morpholine ring by acyclic nonionic bonding514/239.5Carbocyclic ring attached indirectly to the morpholine ring by nonionic bondingExaminersPrimary: Krass, FrederickAttorney, Agent or FirmForeign Patent References
International ClassA61K 031/535AbstractReboxetine is used to treat attention-deficit/hyperactivity disorder.Other References
| |
